title: Interference of immune globulin with measles and rubella immunization.
abstract: Passively acquired antibody may interfere with the active antibody response to live viral vaccines such as measles and rubella. To evaluate the duration of this inhibitory effect, we measured the measles and rubella antibody responses of Apache children immunized with measles, mumps, and rubella vaccine at varying intervals after administration of an immune globulin termed bacterial polysaccharide immune globulin (BPIG). This specific immune globulin contained measles and rubella antibody titers similar to those in standard intramuscularly and intravenously administered immune globulins. Antibody responses to measles vaccine were inhibited for up to 5 months after a BPIG dose of 80 mg IgG per kilogram of body weight, but responses to rubella vaccine were inhibited for only 2 months. Most children who had a decreased measles antibody response to primary measles, mumps, and rubella immunization given 1 1/2 to 4 months after BPIG administration responded to a booster immunization given 6 months after their last BPIG dose. We conclude that high doses of immune globulin (> 10 mg/kg) may inhibit the antibody response to measles for more than 3 months. We propose that the interval between administration of immune globulin and measles and rubella immunization be adjusted on the basis of the dose of immune globulin.
authors.affiliation: Laboratory of Infectious Diseases, Dana-Farber Cancer Institute, Boston, Massachusetts 02115.
authors.forename: G R
authors.initials: GR
authors.lastname: Siber
authors.forename: B G
authors.initials: BG
authors.lastname: Werner
authors.forename: N A
authors.initials: NA
authors.lastname: Halsey
authors.forename: R
authors.initials: R
authors.lastname: Reid
authors.forename: J
authors.initials: J
authors.lastname: Almeido-Hill
authors.forename: S C
authors.initials: SC
authors.lastname: Garrett
authors.forename: C
authors.initials: C
authors.lastname: Thompson
authors.forename: M
authors.initials: M
authors.lastname: Santosham
mesh_terms: D000914:Antibodies, Viral / Q000096:biosynthesis*; D001428:Bacterial Vaccines / Q000494:pharmacology*; D015331:Cohort Studies; D004311:Double-Blind Method; D018073:Haemophilus Vaccines; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D007136:Immunoglobulins / Q000494:pharmacology*; D007223:Infant; D008458:Measles Vaccine / Q000008:administration & dosage / Q000494:pharmacology*; D008459:Measles virus / Q000276:immunology*; D009108:Mumps Vaccine / Q000494:pharmacology; D009109:Mumps virus / Q000276:immunology; D010919:Placebos; D012411:Rubella Vaccine / Q000494:pharmacology*; D012412:Rubella virus / Q000276:immunology*; D013997:Time Factors; D014611:Vaccination
chemical_list: D000914:Antibodies, Viral; D001428:Bacterial Vaccines; D018073:Haemophilus Vaccines; D007136:Immunoglobulins; D008458:Measles Vaccine; D009108:Mumps Vaccine; D010919:Placebos; D012411:Rubella Vaccine; C074704:bacterial polysaccharide immune globulin